Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic presents clinical evidence to ESC

Medtronic presents clinical evidence to ESC

3rd September 2007

Medtronic has announced that it is to present the results of a number of clinical studies to the congress of the European Society of Cardiology (ESC) being held this week in Austria.

The company is to exhibit trial results relating to the management of patients suffering heart failure, in addition to post-myocardial infarction (MI) risk stratification results.

Medtronic will present the results of its Search-MI, Carisma, Sense-HF and Dot-HF studies at the event.

The Search-MI study is a survey designed to evaluate the arrhythmia rate in patients deemed to be at high risk of MI, measuring the prevalence of ventricular arrhythmias and implantable cardioverter-defibrillator interventions in previous heart attack patients.

Carisma has recorded the cardiac arrhythmias and risk stratification of patients after MI, while the Sense-HF and Dot-HF trials measured sensitivity of the InSync Sentry OptiVol feature and diagnostic outcome in heart failure patients.

“The clinical evidence presentations follow closely on CE Mark receipt for the Medtronic CareLink Network and its capabilities of remotely and wirelessly monitoring heart failure patients with implantable cardiac devices in 14 countries around the world,” Medtronic reports.

Last month, Medtronic announced the launch in Europe of the Reveal XT insertable cardiac monitor to offer patients continuous long-term measurement of atrial fibrillation.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.